Welcome To The Gamma Pharmaceuticals HUB China Securities
Message: Gamma Pharmaceuticals Signs Distribution Agreement for $1.03 Million
Admin_profile
ChinaSecurities
Rank: [?]
Administrator
Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Gamma Pharmaceuticals Signs Distribution Agreement for $1.03 Million

posted on Jan 21, 10 09:49AM

LAS VEGAS, NV--(Marketwire - 01/21/10) - Gamma Pharmaceuticals Inc. (Pinksheets:GMPM - News) announced today that the Company has signed a Distribution Agreement for Gamma's branded product ranges. Under the Distribution Agreement, Gamma's monthly sales will ramp-up to $3.4 million. The first monthly purchase order has been accepted with a value of $1.03 million. The Agreement marks a significant milestone for Gamma, as it provides a key piece in the Company's North American Distribution plan. Gamma offers the industry's most distinctive blend of brands, product forms, marketing programs and market message all focused on moving products through large and profitable sales channels. The order received includes the Company's proprietary GELIbites�, GELIthins� and GELIcreams�. Peter Cunningham, Gamma CEO, commented, "We are very excited to have contracted with such a capable partner and are working diligently to piece together a distribution network that will drive high volume, high value sale for years to come. We feel that 2010 will be a game changer for Gamma in every respect as we deliver on our potential and drive shareholder value. We have a deep sales pipeline that we will fill in the weeks and months ahead."

About Gamma Pharmaceuticals Inc.

Gamma Pharmaceuticals Inc., (www.gammapharma.com) is a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally. Gamma's core focus is the marketing and sale of vitamins and nutriceuticals, OTC pharmaceutical products and personal care products in Greater China and the United States. Branded nutritional supplements are sold under the trademarks Brilliant Choice™ children's nutritional supplements featuring the call to action "Mom you've made a brilliant choice for you children's nutrition;" SAVVY™ adult nutritional supplements featuring the call to action, "Be SAVVY Stay Healthy;" and, Jugular Energy Products™ and high performance supplements featuring the call to action, "Go for the Jugular™." Gamma's customer focus is on selling products in the Lifestyle of Health & Sustainability ("LOHAS") marketplace and in the Energy Supplement Market. A series of innovative marketing programs supports Gamma's product sales and retail partners.

At present Gamma manufactures in North America, and distributes in the United States and China. Gamma's products utilize proprietary "Gel Delivery Technology�", to create innovative gel product forms; that give consumers a more pleasant experience. Gel Delivery Technology� characteristics include rapid absorption, convenience and taste great. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress Reduction, Cognition, Well being, Menopause Symptoms, and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma has a total of 36 SKUs and holds licenses for 9 SKUs in China.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this Press Release regarding any impact the quotation of the Company's stock has on the Pink Sheets or the lack thereof on the OTCBB, and any other effects of the above are forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact:



Contact:
Gamma Pharmaceuticals Inc.
Joe Cunningham
(jcunningham@gammapharma.com)
Office: (702) 989 5262
Direct: (651) 204 2048
New Message

Please login to post a reply

Executive Address
Gmpm - small
Gamma Pharmaceuticals
Welcome to Chinasecurities
February 12, 2009
Stock Quote
Hub Leaders